Erythromycin Lactobionate Intravenous

Land: Nya Zeeland

Språk: engelska

Källa: Medsafe (Medicines Safety Authority)

Aktiva substanser:

Erythromycin lactobionate 300mg;  

Tillgänglig från:

Hospira NZ Ltd

INN (International namn):

Erythromycin lactobionate 300 mg

Dos:

300 mg

Läkemedelsform:

Powder for injection

Sammansättning:

Active: Erythromycin lactobionate 300mg  

Enheter i paketet:

Vial, glass, single dose, 5 x 300mg, 1.5 g

Klass:

Prescription

Receptbelagda typ:

Prescription

Tillverkad av:

Sandoz Industrial Products SpA

Produktsammanfattning:

Package - Contents - Shelf Life: Vial, glass, single dose, 5 x 300mg - 1.5 g - 24 months from date of manufacture stored at or below 25°C 24 hours reconstituted stored at or below 25°C 14 days reconstituted stored at 2° to 8°C (Refrigerate, do not freeze)

Tillstånd datum:

1990-08-13

Produktens egenskaper

Data Sheet – New Zealand 

Hosp 1.0 
                 1 

ERYTHROMYCIN LACTOBIONATE INTRAVENOUS 

DESCRIPTION 
Erythromycin is a macrolide antibiotic produced by the growth of
certain strains of _Streptomyces _
_erythreus_. Erythromycin Lactobionate is produced
by the combination of erythromycin and lactobionic 
acid. 

PHARMACOLOGY 
The mode of action of erythromycin has been well characterised
as erythromycin binds to the ribosomes 
of bacteria to inhibit protein synthesis without
affecting nucleic acid synthesis. Erythromycin selectively 
binds only to the ribosomes of bacteria but not to the
cytoplasmic ribosomes of the host cells. This highly 
specific interaction of erythromycin with bacterial ribosomes is a
possible explanation for the low toxicity 
and exceptional clinical safety record of erythromycin. 

Erythromycin diffuses readily into most body fluids, except the
cerebrospinal fluid. However in cases of 
meningeal inflammation, higher concentrations are apparent. 

The apparent volume of distribution of erythromycin is around
45% of body weight in normal subjects. 
This large distribution volume is consistent with the extensive
tissue penetration of erythromycin. 

In the presence of normal hepatic function, erythromycin
is concentrated in the liver and excreted in the 
bile; the effect of hepatic dysfunction on excretion
of erythromycin by the liver is not known. 

Between 12% to 15% of intravenously administered erythromycin is
excreted in active form in the urine. 

The drug is also excreted in the faeces. 

The plasma elimination half-life in patients with normal renal
function is about 2 hours. In severe renal 
impairment the half-life may be prolonged to between 4 and 7 hours. 

MICROBIOLOGY: Erythromycin is bacteriostatic and bactericidal
depending on its concentration and the type 
of organism. It inhibits prote